Abstract
A double-blind cross-over study in 35 patients with ankylosing spondylitis was carried out comparing flurbiprofen (150 mg daily)—a new non-steroidal anti-inflammatory agent—with phenylbutazone (300 mg daily) over a four-week period. Flurbiprofen was well tolerated and shown to have therapeutic efficacy approaching that of phenylbutazone. The results suggest that flurbiprofen may prove a valuable alternative in the treatment of ankylosing spondylitis, and longterm efficacy and tolerance studies are clearly indicated.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- CROMIE B. W. THE FEET OF CLAY OF THE DOUBLE-BLIND TRIAL. Lancet. 1963 Nov 9;2(7315):994–997. doi: 10.1016/s0140-6736(63)90693-7. [DOI] [PubMed] [Google Scholar]
- Calin A., Grahame R., Tudor M., Kennedy L. Letter: "Ankylosing rheumatoid arthritis", ankylosing spondylitis, and HL-A antigens. Lancet. 1974 May 4;1(7862):874–874. doi: 10.1016/s0140-6736(74)90531-5. [DOI] [PubMed] [Google Scholar]
- Chalmers I. M., Cathcart B. J., Kumar E. B., Dick W. C., Buchanan W. W. Clinico-pharmacological studies and clinical evaluation of flurbiprofen. A new non-steroidal antirheumatic agent. Ann Rheum Dis. 1972 Jul;31(4):319–324. doi: 10.1136/ard.31.4.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moll J. M., Wright V. Normal range of spinal mobility. An objective clinical study. Ann Rheum Dis. 1971 Jul;30(4):381–386. doi: 10.1136/ard.30.4.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sturrock R. D., Hart F. D. Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis. 1974 Mar;33(2):129–131. doi: 10.1136/ard.33.2.129. [DOI] [PMC free article] [PubMed] [Google Scholar]